Fibrocystic Breast Disease: Contraindication for Oral Contraceptive Therapy


  • Debbie Cook B.S.N.

    Corresponding author
    1. Debbie Cook is a masters candidate at the University of Illinois at the Medical Center in Nurse-Midwifery. She is a 1974 honors graduate of the University of Wisconsin-Madison, and has experience in teaching and patient care in all aspects of maternity nursing. She is presently involved in cardiopulmonary research in gravid patients. Ms. Cook is a member of Sigma Theta Tau and ACNM.
    Search for more papers by this author

Address correspondence to: Ms. Debbie Cook, % University of Illinois College of Nursing, 845 S. Damen, Chicago, Illinois 60612.


Long-term use of hormonal therapy is controversial in many clinical settings. Estrogens and progestins are known to have profound systemic and cellular effects, many of which are not evident for many years. Oral contraceptives contain significant amounts of these hormones which affect the reproductive organs. A review of breast structure and tissue characteristics, as well as the effects of these hormones on breast tissue, is presented. Emphasis is placed on the need to be cognizant of these similarities and breast tissue receptivity to hormones when considering oral contraceptive therapy.